Stay updated with breaking news from Concurrent Chemoradiation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...
Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care
Regulatory News: NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featur...
Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting ...